SCHEMBL10165787

SCHEMBL10165787

CN(C)C(=O)c1ccc(Nc2ccc(-c3ccc4c(c3)CNCO4)n3ccnc23)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 2/20 0.37
MAPKAPK5 Q8IW41 6/20 0.37
MAP4K1 Q92918 1/20 0.36
MAPK9 P45984 1/20 0.35
MAPK10 P53779 1/20 0.35
ROCK2 O75116 1/20 0.34
CYP1A2 P05177 4/20 0.34
USP2 O75604 3/20 0.34
CYP3A4 P08684 3/20 0.34
CYP2C19 P33261 2/20 0.34
CSNK2A1 P68400 1/20 0.34
CCNT1 O60563 1/20 0.33
CDK1 P06493 1/20 0.33
CDK4 P11802 1/20 0.33
CCNA2 P20248 1/20 0.33
CCND1 P24385 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
CCND3 P30281 1/20 0.33
CDK9 P50750 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10166846 0.89 MAPKAPK5 (0.33) FYNMAPKAPK5
SCHEMBL10166154 0.89 NAMPT (0.39) MAPKAPK5MAP4K1ROCK2TTK
SCHEMBL10166838 0.87 FYN (0.45) FYNMAPK10ROCK2
SCHEMBL10166840 0.86 FYN (0.46) FYNMAPK10ROCK2
SCHEMBL10166021 0.85 TTK (0.42) MAPKAPK5MAPK10TTK
SCHEMBL10166155 0.85 TTK (0.35) FYNMAPKAPK5TTK
SCHEMBL10166351 0.85 MAPKAPK5 (0.43) FYNMAPKAPK5
SCHEMBL10166405 0.84 IKBKB (0.38) CDK1CDK2
SCHEMBL10166029 0.84 MAPT (0.40) ROCK2
SCHEMBL10166358 0.84 BRAF (0.38) MAPKAPK5TTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 FYN 1030/4885MAPKAPK5 19/4885MAP4K1 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.